Roche, Regeneron’s COVID-19 antibody cocktail cuts infection risk
REGEN-COV reduced the risk of symptomatic infections by 81% in a phase 3 prevention trial
Roche and Regeneron’s COVID-19 antibody cocktail REGEN-COV reduced the risk of symptomatic infections by 81% in a phase 3 prevention trial.
The phase 3 2069A trial – run jointly with the US National Institute of Allergy and Infectious Diseases (NIAID) – evaluated the ability of REGEN-COV (casirivimab with imdevimab) to reduce the risk and burden of COVID-19 infection among household contacts of individuals infected with the SARS-CoV-2 virus.
The trial enrolled a total of 1,505 people who were not infected with SARS-CoV-2 at baseline and randomised to receive either one dose of REGEN-COV (1,200mg administered subcutaneously) or placebo.
US Federal Reserve Chairman Promises Very Unusual Recovery as Some Businesses Are Still Suffering
sputniknews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sputniknews.com Daily Mail and Mail on Sunday newspapers.
Advice in pandemic is labor of love for Placitan Scrase
rrobserver.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rrobserver.com Daily Mail and Mail on Sunday newspapers.